CAMBRIAN
Private, clinical-stage biopharmaceutical company focused on developing therapies to prevent and cure age-related diseases.
NEW YORK, USA
More about Cambrian
NJF Capital presents Cambrian.
By the end of this century, there will be 5 times more older people per working-age person than in 2000. By age 75, more than 80% of all people have at least one age-related disorder. More than 40% will have at least two. Medicines that will address the problem of demographic aging must increase healthy lifespan, not prolong the end of life.
Cambrian Biopharma is a distributed R&D company focused on longevity biotech. Cambrian targets the diseases of aging by targeting their underlying causes. By repairing or preventing the upstream causes of disease, Cambrian can prevent or even reverse some of the worst age-related diseases.
Cambrian therapeutics will change the medicine from reactive to proactive and the ultimate goal of Cambrian is to create new therapeutics that will extend lifespan beyond 120.